Vestaron Corporation Overview
Vestaron Corporation was an early commercial pioneer of peptide-based bioinsecticides. These are crop protection products built from insecticidal peptides that originally came from spider venom, optimised by the company and produced through microbial (yeast) fermentation. Its lead active, the SPEAR® peptide, received a new Insecticide Resistance Action Committee mode-of-action classification (IRAC Group 32). That classification places the active at the nicotinic acetylcholine receptor but at a different binding site from neonicotinoids and spinosyns. Vestaron positioned its products as matching the efficacy of conventional synthetics while offering a biological's safety profile: a 4-hour re-entry interval, a 0-day pre-harvest interval, MRL exemption, and low toxicity to pollinators and beneficial insects. After launching SPEAR products in the U.S. from 2018–2020, the company expanded into Canada, Mexico and EU emergency-use markets, and registered a second active, BASIN™, in 2024. In May 2026 Suterra acquired its product and R&D assets, which effectively ended Vestaron's life as an independent commercial operator.
What the company does
Vestaron discovered, optimised, registered and commercialised peptide insecticides. Peptides are short chains of amino acids, smaller than proteins. Its proprietary process starts with natural insecticidal peptides found in spider venom and other venomous animals, then modifies them. Production runs through fermentation (Techleap/citybiz profile, March 2025; Packer, June 2026). The company's long-standing thesis is the following:
-
Six key muscle and nerve receptors account for about 80% of the global insecticide market. Vestaron said in 2022 that it had peptides in its pipeline suited to all six (Global AgInvesting, May 2022).
-
The nicotinic acetylcholine receptor, which SPEAR targets, accounts for about 30% of the roughly USD 18 billion global insecticide market (company-cited figure, repeated across 2019–2022 releases).
-
Peptides can hit validated neuromuscular targets at new binding sites. This avoids cross-resistance with incumbent chemistries while keeping a biological's residue and safety profile.
Company's own description
Recent boilerplate describes Vestaron as leading a global revolution in crop protection by creating novel, effective and sustainable solutions for growers facing the challenges of modern agriculture. It also notes that Vestaron was the first agriculture and food company inducted into the Global CleanTech 100 Hall of Fame (GlobeNewswire, July 2025). Earlier boilerplate (2019) called Vestaron "The Peptide Company." It described the mission as improving the safety, efficacy and sustainability of crop protection by migrating from chemical pesticides to biological peptides (MEDC, April 2019). Vestaron has no annual report because it is private, so this description is taken from press boilerplate.
Business model and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue type | Almost entirely product sales of formulated end-use insecticides. No subscription revenue. Licensing/royalty revenue not disclosed | Preqin describes a direct-sales model around SPEAR and BASIN |
| Pricing | SPEAR LEP priced at parity with conventional synthetic chemistries | IBMA interview (2025) |
| Route to market | Own territory managers plus regional distribution partners (e.g., Wilbur-Ellis in the U.S.; Oxygen AgroShield in Greece; Premier Shukuroglou in Cyprus; Lainco in Iberia) | Vegetable Growers News (Nov 2021); Farm Progress; GlobeNewswire (2024–2025) |
| Manufacturing | Outsourced fermentation: first Capua BioServices (Italy), then a long-term agreement with ADM from October 2024 | AgriBusiness Global; GlobeNewswire (15 Oct 2024) |
| Product/service mix | Product ~100%; service revenue n/d | Analyst characterisation |
Value-chain position
Vestaron sat at the active-ingredient discovery and branded end-product layer of the crop protection value chain. It was asset-light in manufacturing, relying on contract fermentation, and channel-dependent in distribution. It sold through agricultural retail and distributors to growers. It did not own retail or large-scale manufacturing.
Customer types and end-markets
| End-market | Crops / pests | Products |
|---|---|---|
| Specialty field crops (core) | Tree nuts (pistachio, almond: navel orangeworm), grapes, stone fruit, vegetables (crucifers, tomato, pepper), apples (codling moth) | SPEAR LEP, BASIN FLEX, LEPROTEC |
| Protected agriculture / greenhouses | Thrips, whiteflies, aphids, mites | SPEAR T |
| Broad-acre row crops | Cotton (bollworm), soybean (looper), rice, armyworms | SPEAR RC |
| EU emergency-use markets | Tomato (Tuta absoluta), olive (Prays oleae) | SPEAR LEP under Article 53 EUAs |
| Organic production | Bt-based caterpillar control | LEPROTEC (OMRI listed) |
Early-stage plans (c.2012) also targeted animal health, public health and lawn & garden, then sized by the company at a combined USD 15.4 billion (Xconomy). No commercial activity in these non-crop markets has been publicly documented.
Independent characterisation
Vestaron was a technically successful but commercially sub-scale biological insecticide innovator. It achieved the hardest milestones in the category: novel IRAC classification, EPA registration of two new active ingredients, multi-country approvals, a cumulative footprint above one million treated acres, and blue-chip strategic investors. However, it never reached disclosed profitability or the scale needed to fund global registration (EU approval was still pending, targeted for 2027) on its own. The May 2026 sale to a vertically integrated strategic buyer is the classic end-game for venture-funded ag-input innovators. Its IP becomes a portfolio extension for a player with manufacturing scale and global registrations.
Strategy
Stated strategic themes (from releases 2022–2025)
-
Peptide platform breadth. Build a family of peptides, each with a novel mode of action, across the six key neuromuscular receptors (Series C release, 2022).
-
Geographic expansion. Use new capital for new geographies, with Europe as a priority market given synthetic-pesticide restrictions (2019, 2022 and 2025 releases).
-
Crop expansion. Move from specialty crops into broad-acre row crops and new pest categories (Grosvenor add-on, 2022; SPEAR RC launch, 2023).
-
Cost and scale. Secure stable, scalable, lower-cost fermentation supply (ADM agreement, Oct 2024).
-
Regulatory advocacy in the EU. A twofold approach (IBMA interview, 2025): lobby EU policymakers for a faster and more suitable approval pathway for peptide biopesticides, and support grower-led EUA petitions in the meantime.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail |
|---|---|---|
| Oct 2024 | ADM manufacturing collaboration | Long-term production agreement with ADM's precision fermentation unit |
| Mar 2025 | Growth financing | More than USD 20M raised to accelerate commercialisation in the U.S. and Europe |
| 2,025 | EU EUA expansion | Second-cycle EUAs (IT/GR/CY), new Portugal EUA, new crop (olive in Italy) |
| Jul 2025 | Lainco partnership (Iberia) | Spanish agrochemical company (90-year history) as European commercial partner |
| May 2026 | Strategic exit | Sale of product lines, actives, pipeline and R&D assets to Suterra |
ESG / sustainability commitments
Positioning centres on pollinator safety, worker safety (4-hour REI), biodiversity and reduced synthetic use. No quantified emissions targets were found.
Medium-term targets / guidance
None disclosed, other than a company statement that EU full approval of SPEAR LEP was hoped for in 2027 (IBMA, 2025). After the asset sale, this milestone now falls to Suterra.
Products & Services
All products below were Vestaron-owned until the May 2026 Suterra acquisition. Ownership of SPEAR and BASIN lines has since passed to Suterra.
SPEAR® LEP
| Attribute | Detail |
|---|---|
| Description | Peptide-based bioinsecticide for lepidopteran larvae (caterpillars, loopers, worms) in field crops |
| Active / MoA | SPEAR peptide. IRAC Group 32. Acts on the nicotinic acetylcholine receptor at a site distinct from neonicotinoids and spinosad. No known resistance or cross-resistance |
| Key label attributes | 4-hour REI, 0-day PHI, MRL exempt, practically non-toxic to pollinators. No special handling/storage |
| Usage note | Designed to be tank-mixed with Bt products. Bt disrupts the larval midgut and lets the peptide reach nervous-system targets (Farm Progress; Knowde) |
| Target crops | Tree nuts (navel orangeworm), apples (codling moth), grapes (European grapevine moth), vegetables, tomato |
| Registration | U.S. full approval 2018; registered in all 50 states. Commercial launch 2020. Canada (in use since 2020). Mexico (Nov 2021). EU dossier filed 2022, approval hoped for 2027 |
| EU EUAs | Greece (2024, 2025, fourth in Jul 2025), Italy (2024, 2025; olives 2025), Cyprus (2024, 2025), Portugal (Jul 2025) |
| Pricing | Parity with conventional synthetics (IBMA) |
| EUA use rate (Greece) | 3 applications every 5–15 days at 1–2 L/ha |
SPEAR® T Liquid Concentrate
| Attribute | Detail |
|---|---|
| Description | Greenhouse bioinsecticide |
| Target pests | All four major greenhouse pests: thrips, whiteflies, aphids, mites |
| Registration | First EPA-approved Vestaron biopesticide (2018) |
| Target customer | Greenhouse vegetable and ornamental growers |
SPEAR® RC
| Attribute | Detail |
|---|---|
| Description | SPEAR formulation positioned for broad-acre row crops |
| Target pests | Cotton bollworm, soybean looper, armyworm |
| Crops | Cotton, soybean, rice, other broad-acre crops |
| Launch | Introduced to growers at early-2023 conferences (Mid-South Farm & Gin Show, Commodity Classic) |
| Attributes | IRAC 32, 0-day PHI, 4-hour REI, MRL exempt |
BASIN™ / BASIN™ FLEX
| Attribute | Detail |
|---|---|
| Description | Vestaron's second peptide active ingredient, derived from modified spider venom |
| MoA | Targets the same receptor as SPEAR but at another site |
| Target pests | Lepidoptera in stone fruit, tree nuts, vegetables, specialty crops |
| Attributes | 4-hour REI, 0-day PHI, MRL exemption |
| Regulatory | EPA submission 15 Mar 2022 (Q4 2022 launch was targeted then but slipped). EPA unconditional registration Mar 2024. COFEPRIS AI registration 22 Mar 2024. Some aggregators reported earlier Mexico approval (sp-edge), a discrepancy |
| Commercial launch | Expected in or before 2025 (company, Mar 2024). Actual launch date n/d; product was described as "upcoming" in 2025 aggregator profiles |
LEPROTEC® (liquid)
| Attribute | Detail |
|---|---|
| Description | Liquid formulation of Bacillus thuringiensis subsp. kurstaki strain EVB-113-19 |
| Target | Loopers, worms, caterpillars in outdoor food, non-food and greenhouse crops |
| Positioning | OMRI listed (organic). Designed as the companion to SPEAR LEP |
| Source | Global AgInvesting (May 2022); Knowde |
LEPROTEC® WG
| Attribute | Detail |
|---|---|
| Description | Water-dispersible granule variant of LEPROTEC (Btk) |
| Detail | Specifications n/d beyond listing on vestaron.com product menu |
Pipeline (transferred to Suterra)
-
Additional active ingredients and product formulations under development were included in the Suterra sale (Suterra, May 2026).
-
In 2022 the company claimed pipeline peptides addressing all six major insecticidal neuromuscular receptors (Global AgInvesting).
-
In early 2014 the company reported more than 50 unique spider-venom peptides with novel sites of action identified (Xconomy funding feed).
-
Historic trait ambitions: the platform was described as supporting both sprayable products and insect-resistant crop traits (MEDC 2019; Global AgInvesting 2022). No trait product has been commercialised.
Financial Narrative
Vestaron is private and has not published audited financial statements, revenue, profit or balance-sheet data for any year. Every line item below is therefore "n/d". The tables are kept to preserve the dossier structure for automated capture.
Income statement
Note on dividends: no dividends have ever been reported. Zero is shown because venture-backed preferred-stock companies at this stage do not pay dividends. Treat as analyst inference.
Margins (%)
Revenue CAGR FY2021–FY2025: n/d.
Disclosed capital-raising data (the only verifiable financial series)
Sources: Series B-1 USD 18M (Novo Holdings, Feb 2021); Series C USD 82M plus USD 10M add-on (Global AgInvesting; NCBiotech, 2022); round of more than USD 20M (Techleap/citybiz; Preqin, Mar 2025). Dealroom lists further late-stage tranches of USD 18.3M and USD 61.2M whose dates and relationship to the rounds above could not be reconciled. This is a source discrepancy.
Commentary on trends, inflections and drivers
Without reported financials, the analysis must rely on proxies:
Funding cadence as a burn proxy: Vestaron raised about USD 130M in 2021–2022. It then went about 2.5 years without a publicly announced round, until the 2025 raise of just over USD 20M, a much smaller ticket. Reported Dealroom valuations rose from about USD 200M to about USD 410M. The step-down in round size, combined with a change of CEO in 2024 (CFO elevated to CEO), suggests a pivot from growth funding to capital discipline and runway extension. This is analyst inference.
Manufacturing cost inflection: The October 2024 ADM agreement was explicitly framed around scale and lower cost of goods sold, through access to bio-based feedstocks and fermentation capacity (i3/Cleantech Group summary; GlobeNewswire). This implies gross margin was a key constraint before 2024.
Commercial traction: Cumulative adoption passed 1 million acres by March 2025 (citybiz/Techleap). California pistachio share rose from 3% (2020) to 5% (2021). These are real but modest penetration numbers in a single, high-value niche.
End-state: The May 2026 asset sale to Suterra, with no disclosed price, is consistent with a company that had validated its technology but lacked the self-funded path to profitability and global registration. Deal value is n/d. Whether investors recovered their capital is unknown.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Operational Segment Details
| Operational segment (analyst construct) | Contents | Products |
|---|---|---|
Specialty Field Crops | Lepidopteran control in tree nuts, fruit, vegetables, vines | SPEAR LEP, BASIN FLEX, LEPROTEC, LEPROTEC WG |
Protected Agriculture | Greenhouse sucking/rasping pests | SPEAR T Liquid Concentrate |
Broad-Acre Row Crops | Cotton, soybean, rice lepidopterans | SPEAR RC |
International (Mexico, Canada, EU EUAs) | Regional registrations and emergency-use sales | SPEAR LEP, BASIN (Mexico AI) |
Revenue by Segment (%)
| Metric | FY2020 | FY2021 |
|---|---|---|
SPEAR share of California pistachio insecticide market (%) | 3 | 5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis — Dividends paid
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2025 |
|---|---|---|---|
Disclosed equity raised (USD Mn) | 18 | 92 | 20 |
Country Overview
| Country | Market status | First access | Basis |
|---|---|---|---|
United States | Core market. SPEAR registered in all 50 states. BASIN registered 2024 | 2018 (SPEAR-T); 2020 (SPEAR LEP launch) | EPA registrations |
Canada | SPEAR LEP in use | 2,020 | IBMA; AgriBusiness Global |
Mexico | SPEAR-Lep registered; BASIN AI registered | Nov 2021; Mar 2024 | COFEPRIS |
Greece | EUAs (tomato), four granted by July 2025 | Feb 2024 | Article 53 EUA |
Italy | EUAs (tomato; olive from 2025) | Mar 2024 | Article 53 EUA |
Cyprus | EUAs (tomato) | May 2024 | Article 53 EUA |
Portugal | EUA (tomato) | Jul 2025 | Article 53 EUA |
Spain, France | Country websites exist; commercial status n/d | — | vestaron.com |
Brazil | Interest noted; no registration found | — | NCBiotech (2022) |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (private) |
Dividend history / policy | None paid |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | n/d. Only a 2014 SEC-reported debt raise of USD 1.27M is known |
Exit | Asset sale to Suterra, May 2026. Consideration n/d |
Capital Markets Data
| Metric | FY2025 |
|---|---|
Reported post-money valuation (USD Mn) | 410 |
Analyst Conclusions
Management guidance
No financial guidance has ever been published. The last public operational guidance was the hoped-for 2027 EU approval of SPEAR LEP. Following the May 2026 sale, forward strategy belongs to Suterra. Suterra plans to manufacture its own branded SPEAR LEP in 2026, build IPM programmes combining pheromones with peptides, use its existing European and African registrations, and explore broad-acre partnerships in corn and cotton.
Consensus
None (private; no coverage).
Bull case (for the Vestaron technology under Suterra ownership)
-
Faster international rollout. Suterra's vertically integrated manufacturing in Bend, Oregon and its registrations in more than 30 countries remove Vestaron's two biggest constraints: scale and global reach.
-
Validated product. More than 1M acres treated and repeat EUAs in four EU countries show real demand.
-
Large-acre upside. Broad-acre expansion (SPEAR RC; corn and cotton interest) could add revenue many times the specialty-crop base.
Bear case
-
Equity value unknown. No deal price was disclosed. If the sale was distressed, Vestaron shareholders may have recovered little of more than USD 200M invested.
-
Regulatory bottleneck remains. The EU process is still slow, so full EU value may not arrive before 2027 or later, regardless of owner.
-
Integration risk. A pheromone-focused company must now master peptide fermentation and pipeline R&D, and key Vestaron scientific staff may not transfer.
Catalysts and monitorables (next 12 months)
-
Launch of Suterra-branded SPEAR LEP and confirmation of supply continuity (2026)
-
Whether the ADM manufacturing agreement transfers to Suterra or is replaced
-
2026–2027 EU EUA renewals and progress of the EU full-approval dossier
-
Commercial launch status of BASIN FLEX under Suterra
-
Any formal dissolution, liquidation or distribution announcement by Vestaron Corporation
-
Retention of Vestaron's R&D team at the Kalamazoo facility
Analyst verdict
Vestaron Corporation is a case study in a pattern common to agricultural biotechnology: scientific and regulatory success that did not translate into a standalone business. Over two decades, the company turned a spider-venom peptide concept from the University of Connecticut into two EPA-registered active ingredients. It earned a new IRAC mode-of-action class, product registrations in the United States, Canada and Mexico, and repeat emergency authorisations across four EU member states. Few biological start-ups clear these hurdles. Its products had a strong regulatory profile (0-day PHI, 4-hour REI, MRL exemption), were priced at parity with synthetics, and had been used on more than one million acres.
The commercial and financial record is much weaker, and largely opaque. Vestaron never disclosed revenue or profitability. It raised more than USD 200 million across numerous rounds and went through four CEO transitions. Its EU growth was capped by a regulatory process that the company itself called unfit for peptides. Its 2025 raise, smaller than the 2022 Series C, and the elevation of its CFO to CEO pointed to runway management rather than expansion. The sale of all product lines, actives, pipeline and R&D assets to Suterra in May 2026 should be read as a strategic exit by a company that could not scale independently. Whether that exit created value for shareholders cannot be assessed, because the price was not disclosed.
For institutional readers, Vestaron Corporation itself is no longer an investable or partner-relevant operating entity. The relevant counterparty for SPEAR, BASIN and the peptide pipeline is now Suterra and The Wonderful Company. The technology's long-term value depends on Suterra's ability to secure full EU approval, launch BASIN, and break into broad-acre markets. Verdict: technology validated; independent company concluded; monitor via Suterra.
SOURCE LIST (primary references used)
-
Suterra press release, "Suterra Acquires Vestaron's R&D Assets and Product Lines," 6 May 2026 (suterra.com); coverage in CropLife, Spudman, Fruit Growers News, FreshPlaza, AgriBusiness Global, Good Fruit Grower (May–Jul 2026)
-
The Packer, "Suterra Vestaron Acquisition Signals Transition From the Chemistry Boom to the Biotechnology Boom," 5 Jun 2026
-
vestaron.com (product menu, country sites, acquisition banner), accessed Oct 2026
-
GlobeNewswire / partner reposts: ADM agreement (15 Oct 2024); Portugal EUA (8 Jul 2025); Greece/Italy EUAs (22 Jul 2025)
-
Global Agriculture: CEO transition (2 Feb 2024); BASIN Mexico (22 Mar 2024)
-
HortiDaily: Estupinan permanent CEO (2024)
-
AgriBusiness Global: Collins chair (2023); BASIN Mexico; Capua BioServices; SPEAR RC
-
Vegetable Growers News / Produce Processing: EUAs (2024–2025); Mexico approval (Nov 2021)
-
IBMA: Bernard Blum Award decade interview (2025)
-
Novo Holdings: Series B-1 (16 Feb 2021); Global AgInvesting and NCBiotech: Series C (2022)
-
AgFunderNews / Global AgInvesting: Series B (2019); MEDC (Apr 2019); Xconomy (2012–2014); Global Venturing (Jan 2014); GlobeNewswire (Sep 2011); WMed news archive
-
Aggregators (lower reliability, flagged in text): Preqin, Dealroom, Owler, Techleap/citybiz, i3/Cleantech Group, kscope, sp-edge
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / notes |
|---|---|---|---|
Juan Estupinan | CEO & President; Board member; CFO & Treasurer | Joined as CFO May 2022; interim CEO Feb 2024; permanent CEO 2024 | Described as having financial and business leadership experience across multiple industries |
Ben Cicora | SVP Sales & Marketing (title as of 2021–2023) | — | Led Mexico launch and SPEAR RC launch |
Dayna Collett, PhD | Senior Manager, Field Development (2023) | — | Presented SPEAR row-crop data |
Executive Leadership Team — Steven Hartmeier
| Name | Tenure | Context |
|---|---|---|
Steven Hartmeier | 2011–2013 (approx.) | Ex-President of Suterra (notable link to the eventual acquirer) |
John C. Sorenson, PhD | Interim from Sep 2013; CEO from Jan 2014; died in office (c. Feb 2018) | Took Vestaron from R&D start-up to first product launch |
Anna Rath | c.2019 – 2 Feb 2024 | Led commercial launch of SPEAR and the 2019–2022 fundraising. Departure not explained publicly |
Board of Directors
| Name | Role | Affiliation / background | Since |
|---|---|---|---|
James C. Collins Jr. | Chair; Executive Director | Former CEO of Corteva. Led the creation and spin-out of Corteva from the Dow/DuPont merger. More than 35 years in agriculture | Board Jan 2023; Chair May 2023 |
Juan Estupinan | Director | CEO | 2024 |
Randy C. Papadellis | Director | Former President & CEO, Ocean Spray Cranberries | — |
Adam Wieschhaus | Director (as of 2021) | Director, Northpond Ventures | Feb 2021 |
Board observers (2022) | Ariel Barack (Ordway), Mike Wilbur (Cavallo/Wilbur-Ellis), Craig Herron (iSelect) | Series C investors | May 2022 |
Major Shareholders
| Investor | Type | First known participation |
|---|---|---|
Novo Holdings | Life-science investor (Denmark) | 2019 (led Series B) |
Northpond Ventures | Venture capital | 2021 (led B-1) |
Ordway Selections | Investor | 2022 (co-led Series C) |
Cavallo Ventures (Wilbur-Ellis) | Corporate venture | 2,021 |
Syngenta Ventures | Corporate venture | By 2021 |
CGC Ventures (Continental Grain) | Corporate venture | By 2021 |
Anterra Capital | Venture capital (Rabobank / FIL-backed) | c.2014–2016 |
Cultivian Sandbox Ventures | Venture capital | By mid-2010s |
Open Prairie Ventures | Venture capital | By 2012 |
Pangaea Ventures | Venture capital | 2,012 |
iSelect | Venture capital | By 2022 |
Agronautic Ventures, Fortistar, Endeavor8 | Investors | 2,022 |
Grosvenor Food & AgTech | Investor | 2022 (USD 10M) |
SW Michigan First Life Science Fund; Michigan Strategic Fund; Michigan Accelerator Fund | Regional / public funds | 2007–2012 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning vs. Vestaron |
|---|---|---|
Corteva Agriscience (spinosyns: spinosad, spinetoram) | Lepidoptera in specialty crops | Incumbent at the same receptor (different site). Scale leader |
Bayer Crop Science | Synthetic and biological insecticides | Scale, channel power |
Syngenta (incl. Syngenta Biologicals) | Lepidoptera, greenhouse | Also an investor in Vestaron (Syngenta Ventures) |
BASF | Insecticides | Broad portfolio |
FMC | Diamides (lepidopteran leaders) | Incumbent synthetic standard in many Vestaron crops |
Certis Biologicals (Mitsui) | Bt and biological insecticides | Direct competitor in Bt and biological lepidopteran control |
Marrone Bio (now part of Bioceres) | Biological insecticides | Biological peer |
Biotalys (Belgium, listed) | Protein-based biocontrols | Closest technology analogue (proteins/peptides) |
GreenLight Biosciences | RNA-based insecticides | Next-generation biological modality |
Provivi | Pheromones | Biological, but a different modality |
Suterra (acquirer) | Pheromones / mating disruption | Former competitor for biological spend; now owner |
Recent Developments
To meet the minimum entry count, the register extends back to January 2024 for context and marks the window boundary.



